(R)-Phenylpiracetam – (949925-07-9)

MRZ-9547, also known as (R)-phenylpiracetam, (R)-phenotropil, or (R)-fonturacetam, is a selective dopamine reuptake inhibitor (IC50 = 14.5 μM) developed by Merz Pharma.

It is the (R)-enantiomer of the racetam and nootropic phenylpiracetam. MRZ-9547 was under development for the treatment of fatigue associated with Parkinson’s disease and was in phase 1 clinical trials for this indication in June 2014.

However, no recent development has been reported as of 2025. The drug has also shown pro-motivational effects in animal models, reversing motivational deficits induced by dopamine-depleting agents. MRZ-9547 was first described in the scientific literature in 2014.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/MRZ-9547
https://www.medchemexpress.com/r-phenylpiracetam.html
https://www.medkoo.com/products/19216
https://pubmed.ncbi.nlm.nih.gov/25319446/
https://pubmed.ncbi.nlm.nih.gov/24964269/